Wan-Hsuan Lee, Chien-Chin Lin, Cheng-Hong Tsai, Feng-Ming Tien, Min-Yen Lo, Mei-Hsuan Tseng, Yuan-Yeh Kuo, Shan-Chi Yu, Ming-Chih Liu, Chang-Tsu Yuan, Yi-Tsung Yang, Ming-Kai Chuang, Bor-Sheng Ko, Jih-Luh Tang, Hsun-I Sun, Yi-Kuang Chuang, Hwei-Fang Tien, Hsin-An Hou, Wen-Chien Chou
In 2022, two novel classification systems for myelodysplastic syndromes/neoplasms (MDS) have been proposed: the International Consensus Classification (ICC) and the 2022 World Health Organization (WHO-2022) classification. These two contemporary systems exhibit numerous shared features but also diverge significantly in terminology and the definition of new entities. Thus, we retrospectively validated the ICC and WHO-2022 classification and found that both systems promoted efficient segregation of this heterogeneous disease...
April 9, 2024: Blood Cancer Journal